Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) Ability to Predict Chronic Kidney Disease and the Number of Readmissions in Patients Admitted in the Emergency Department - a Longitudinal Prospective Study

NCT04008810 is registered in ClinicalTrials.gov with Hillerod Hospital, Denmark as lead sponsor.

NCT NCT04008810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04008810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) Ability to Predict Chronic Kidney Disease and the Number of Readmissions in Patients Admitted in the Emergency Department - a Longitudinal Prospective Study
Lead sponsor
Hillerod Hospital, Denmark
Phase
Observational
Overall status
Completed
Start date
October 3, 2019
Completion date
June 3, 2024
Enrollment
1,032 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, aki, chronic kidney diseases, ckd, emergency department, neutrophil gelatinase-associated lipocalin, ngal